Roadmap for New Opportunities in Melanoma Research

Seminars in Oncology

Volumn 34, Issue 6, 2007, Pages 566-576

  Herlyn, Meenhard ^a   Halaban, Ruth ^b   Ronai, Ze'ev ^c   Schuchter, Lynn ^d   Berwick, Marianne ^e   Pinkel, Daniel ^f  

^a WISTAR INSTITUTE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BURNHAM INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BIOLOGICAL MARKER; DACARBAZINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; TEMOZOLOMIDE;

APOPTOSIS; ARTICLE; CANCER PREVENTION; CELL TRANSFORMATION; DIAGNOSTIC IMAGING; GENE MUTATION; GENETIC RISK; HUMAN; IMMUNE RESPONSE; MELANOCYTE; MELANOMA; METASTASIS; MOLECULAR EPIDEMIOLOGY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK FACTOR; TUMOR CELL CULTURE; TUMOR CLASSIFICATION; TUMOR RESISTANCE; ULTRAVIOLET IRRADIATION;

HUMANS; MELANOMA; RESEARCH; SKIN NEOPLASMS;

EID: 36849044065     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.09.004     Document Type: Article

References (53)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Elder D.E., and Xu X. The approach to the patient with a difficult melanocytic lesion. Pathology 36 (2004) 428-434
3. Chorny J.A., Barr R.J., Kyshtoobayeva A., et al. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions. Mod Pathol 16 (2003) 525-529
4. Strungs I. Common and uncommon variants of melanocytic naevi. Pathology 36 (2004) 396-403
5. Barnhill R.L., Argenyi Z.B., From L., et al. Atypical Spitz nevi/tumors: Lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol 30 (1999) 513-520
6. Wick M.R., and Patterson J.W. Cutaneous melanocytic lesions: Selected problem areas. Am J Clin Pathol 124 suppl (2005) S52-S83
7. Sondak V.K., and Messina J.L. Current status of biomarkers for melanoma metastasis. IDrugs 9 (2006) 627-631
8. Wolnicka-Glubisz A., and Noonan F.P. Neonatal susceptibility to uv induced cutaneous malignant melanoma in a mouse model. Photochem Photobiol Sci 5 (2006) 254-260
9. Kabbarah O., and Chin L. Advances in malignant melanoma: Genetic insights from mouse and man. Front Biosci 11 (2006) 928-942
10. Li W., Rusiniak M.E., Chintala S., et al. Murine Hermansky-Pudlak syndrome genes: Regulators of lysosome-related organelles. Bioessays 26 (2004) 616-628
11. Sturm R.A. A golden age of human pigmentation genetics. Trends Genet 22 (2006) 464-468
12. Baxter L.L., Hou L., Loftus S.K., et al. Spotlight on spotted mice: A review of white spotting mouse mutants and associated human pigmentation disorders. Pigment Cell Res 17 (2004) 215-224
13. Tachibana M., Kobayashi Y., and Matsushima Y. Mouse models for four types of waardenburg syndrome. Pigment Cell Res 16 (2003) 448-454
14. Yoshida H., Kunisada T., Grimm T., et al. Review: Melanocyte migration and survival controlled by SCF/c-Kit expression. J Investig Dermatol Symp Proc 6 (2001) 1-5
15. Rawls J.F., Mellgren E.M., and Johnson S.L. How the zebrafish gets its stripes. Dev Biol 240 (2001) 301-314
16. Widlund H.R., and Fisher D.E. Microphthalamia-associated transcription factor: A critical regulator of pigment cell development and survival. Oncogene 22 (2003) 3035-3041
17. Halaban R. Culture of melanocytes from normal, benign and malignant lesions. In: Freshney R.I., and Pfranger R. (Eds). Culture of Human Tumor Cells (2003), Wiley, New York, NY 289-318
18. Toyofuku K., Wada I., Spritz R.A., et al. The molecular basis of oculocutaneous albinism type 1 (OCA1): Sorting failure and degradation of mutant tyrosinases results in a lack of pigmentation. Biochem J 355 (2001) 259-269
19. Hearing V.J. Biogenesis of pigment granules: A sensitive way to regulate melanocyte function. J Dermatol Sci 37 (2005) 3-14
20. Halaban R., Svedine S., Cheng E., et al. Endoplasmic reticulum retention is a common defect associated with tyrosinase-negative albinism. Proc Natl Acad Sci USA 97 (2000) 5889-5894
21. Francis E., Wang N., Parag H., et al. Tyrosinase maturation and oligomerization in the endoplasmic reticulum require a melanocyte-specific factor. J Biol Chem 278 (2003) 25607-25617
22. Smalley K.S., Lioni M., and Herlyn M. Life isn't flat: Taking cancer biology to the next dimension. In Vitro Cell Dev Biol Anim 42 (2006) 242-247
23. Markovic S.N., Erickson L.A., Rao R.D., et al. Malignant melanoma in the 21st century, part 1: Epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 82 (2007) 364-380
24. Laud K., Marian C., Avril M.F., et al. Comprehensive analysis of cdkn2a (p16INK4a/p14ARF) and CDKN2b genes in 53 melanoma index cases considered to be at heightened risk of melanoma. J Med Genet 43 (2006) 39-47
25. Goldstein A.M., Chan M., Harland M., et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across genomel. Cancer Res 66 (2006) 9818-9828
26. Tucker M.A., and Goldstein A.M. Melanoma etiology: Where are we?. Oncogene 22 (2003) 3042-3052
27. Kanetsky P.A., Rebbeck T.R., Hummer A.J., et al. Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res 66 (2006) 9330-9337
28. Landi M.T., Bauer J., Pfeiffer R.M., et al. Mc1r germline variants confer risk for brafmutant melanoma. Science 313 (2006) 521-522
29. Ha L., Noonan F.P., De Fabo E.C., et al. Animal models of melanoma. J Investig Dermatol Symp Proc 10 (2005) 86-88
30. Chin L. The genetics of malignant melanoma: Lessons from mouse and man. Nat Rev Cancer 3 (2003) 559-570
31. Chin L., Garraway L.A., and Fisher D.E. Malignant melanoma: Genetics and therapeutics in the genomic era. Genes Dev 20 (2005) 2149-2182
32. Packer L.M., Pavey S.J., Boyle G.M., et al. Gene expression profiling in melanoma identifies novel downstream effectors of p14ARF. Int J Cancer (2007) 784-790
33. Dissanayake S.K., Wade M.S., Johnson C.E., et al. The Wnt5a/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem (2007) 17259-17271
34. Schepsky A., Bruser K., Gunnarsson G.J., et al. The microphthalmia-associated transcription factor mitf interacts with beta-catenin to determine target gene expression. Mol Cell Biol 26 (2006) 8914-8927
35. Larue L., and Delmas V. The wnt/beta-catenin pathway in melanoma. Front Biosci 11 (2006) 733-742
36. Nickoloff B.J., Hendrix M.J., Pollock P.M., et al. Notch and noxa-related pathways in melanoma cells. J Investig Dermatol Symp Proc 10 (2005) 95-104
37. Hirano Y., and Ronai Z. A new function for p53 ubiquitination. Cell 127 (2006) 675-677
38. Ivanov V.N., Bhoumik A., and Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 22 (2003) 3152-3161
39. Bar-Eli M. Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res 14 (2001) 78-85
40. Hendrix M.J., Seftor E.A., Seftor R.E., et al. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 7 (2007) 246-255
41. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 10 (2004) 909-915
42. Maker A.V., et al. Tumor regression and autoimmunity in patients treated with cytotoxic t lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Ann Surg Oncol 12 (2005) 1005-1016
43. Maker A.V., Attia P., and Rosenberg S.A. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175 (2005) 7746-7754
44. Kasper B., D'Hondt V., and Vereecken P. Novel treatment strategies for malignant melanoma: A new beginning?. Crit Rev Oncol Hematol 62 (2007) 16-22
45. Ward R.C., and Kaufman H.L. Targeting costimulatory pathways for tumor immunotherapy. Int Rev Immunol 26 (2007) 161-196
46. Petrulio C.A., Kim-Schulze S., and Kaufman H.L. The tumour microenvironment and implications for cancer immunotherapy. Expert Opin Biol Ther 6 (2006) 671-684
47. + human regulatory T cells in vivo: Kinetics of treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 120 (2007) 2723-2733
48. Cohen A.D., Diab A., Perales M.A., et al. Agonist antigitr antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res 66 (2006) 4904-4912
49. Ramirez-Montagut T., Chow A., Hirschhorn-Cymerman D., et al. Glucocorticoid-induced tnf receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 176 (2006) 6434-6442
50. Bielenberg D.R., Hida Y., Shimizu A., et al. Semaphorin 3f, a chemorepulsant for endothelial cells, induces a poorlyvascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 114 (2004) 1260-1271
51. Nair S., Boczkowski D., Fassnacht M., et al. Vaccination against the forkhead family transcription factor foxp3 enhances tumor immunity. Cancer Res 67 (2007) 371-380
52. + T-cell dependent. Blood 108 (2006) 3818-3823
53. Flaherty K.T. Sorafenib: Delivering a targeted drug to the right targets. Expert Rev Anticancer Ther 7 (2007) 617-626